(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons.
- 0 Comments
- FY2018